TW200902070A - Compositions that include a hydrophobic compound and a polyamino acid conjugate - Google Patents

Compositions that include a hydrophobic compound and a polyamino acid conjugate Download PDF

Info

Publication number
TW200902070A
TW200902070A TW097117167A TW97117167A TW200902070A TW 200902070 A TW200902070 A TW 200902070A TW 097117167 A TW097117167 A TW 097117167A TW 97117167 A TW97117167 A TW 97117167A TW 200902070 A TW200902070 A TW 200902070A
Authority
TW
Taiwan
Prior art keywords
composition
group
polymer
tumor
drug
Prior art date
Application number
TW097117167A
Other languages
English (en)
Chinese (zh)
Inventor
Sang Van
Yu-Cheng Song
Xing-He Wang
Zheng Hou
zhong-ling Feng
Gang Zhao
Lei Yu
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of TW200902070A publication Critical patent/TW200902070A/zh

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW097117167A 2007-05-09 2008-05-09 Compositions that include a hydrophobic compound and a polyamino acid conjugate TW200902070A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91690307P 2007-05-09 2007-05-09

Publications (1)

Publication Number Publication Date
TW200902070A true TW200902070A (en) 2009-01-16

Family

ID=39864977

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097117167A TW200902070A (en) 2007-05-09 2008-05-09 Compositions that include a hydrophobic compound and a polyamino acid conjugate

Country Status (11)

Country Link
US (2) US8197828B2 (enExample)
EP (1) EP2155255B1 (enExample)
JP (1) JP5341879B2 (enExample)
KR (1) KR20100017540A (enExample)
CN (1) CN101678123B (enExample)
CA (1) CA2683590A1 (enExample)
DK (1) DK2155255T3 (enExample)
ES (1) ES2430380T3 (enExample)
PT (1) PT2155255E (enExample)
TW (1) TW200902070A (enExample)
WO (1) WO2008141107A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2472812C2 (ru) 2005-12-05 2013-01-20 НИТТО ДЕНКО КОРПОРЭЙШН (Джэпэн/Джэпэн) Конъюгаты полиглутамат-аминокислота и способы
JP5341879B2 (ja) 2007-05-09 2013-11-13 日東電工株式会社 疎水性化合物及びポリアミノ酸複合体を含む組成物
US20100093935A1 (en) * 2008-10-15 2010-04-15 Nitto Denko Corporation Method of preparing polyglutamate conjugates
WO2011075483A1 (en) * 2009-12-16 2011-06-23 Nitto Denko Corporation Controlled synthesis of polyglutamic acid
ES2677478T3 (es) * 2012-04-12 2018-08-02 Nitto Denko Corporation Conjugados de copolímero
CN104736179B (zh) 2012-05-07 2017-09-26 日东电工株式会社 具有接头的聚合物缀合物
KR101494639B1 (ko) * 2013-05-15 2015-02-23 고려대학교 산학협력단 엽산 Cy7계 치료진단용 약물 전달 시스템 및 이것의 제조방법
RU2676680C2 (ru) 2014-04-07 2019-01-10 Нитто Денко Корпорейшн Новые гидротропы на основе полимера для доставки гидрофобного лекарственного средства

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59186924A (ja) 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
EP0150184A1 (fr) 1983-07-01 1985-08-07 Battelle Memorial Institute Polypeptide biodegradable et son utilisation pour le relargage progressif de medicaments
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
DE3581471D1 (de) 1984-10-19 1991-02-28 Battelle Memorial Institute Durch mikroorganismen abbaubares polypeptid und seine verwendung fuer die fortschreitende abgabe von medikamenten.
CS254355B1 (en) 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
CH667874A5 (fr) 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
CA2013755C (en) * 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
ATE185489T1 (de) 1990-04-10 1999-10-15 Imarx Pharmaceutical Corp Polymere als kontrastmittel bei magnetischer resonanz
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US6517824B1 (en) 1990-05-14 2003-02-11 University Of Medicine & Denistry Of New Jersey Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5372807A (en) 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5660822A (en) 1990-05-14 1997-08-26 University Of Medicine & Dentistry Of N.J. Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US6762188B1 (en) 1990-06-19 2004-07-13 Smithkline Beecham Corporation Pharmaceutically active benzoquinazoline compounds
GB9013615D0 (en) 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9120653D0 (en) 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5384333A (en) 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5449720A (en) 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5548064A (en) 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
GB2282384B8 (en) 1993-08-18 1997-09-04 Europ Economic Community Drug delivery agents incorporating mitomycin
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US5980862A (en) 1995-06-02 1999-11-09 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US5762909A (en) 1995-08-31 1998-06-09 General Electric Company Tumor targeting with polymeric molecules having extended conformation
DE19548114C2 (de) 1995-12-21 2000-04-27 Deutsches Krebsforsch Konjugat, umfassend einen Wirkstoff, ein Polypeptid und einen Polyether
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
EP0932399B1 (en) 1996-03-12 2006-01-04 PG-TXL Company, L.P. Water soluble paclitaxel prodrugs
US6030941A (en) 1996-05-01 2000-02-29 Avi Biopharma, Inc. Polymer composition for delivering substances in living organisms
US5929198A (en) 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6229009B1 (en) 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US6528061B1 (en) 1997-09-04 2003-03-04 Pasteur Institut Immunogenic polypeptides that mimic a surface polysaccharide antigen of a pathogenic microorganism, method for obtaining the same, and their use in vaccine compositions
JP3390965B2 (ja) 1997-09-12 2003-03-31 理化学研究所 糖結合スフィンゴシンを含有するポリマー化合物
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US20040170563A1 (en) 1997-10-27 2004-09-02 Meade Thomas J. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US5981564A (en) 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US20030124143A1 (en) 1998-08-31 2003-07-03 Armelle Phalipon Methods for selecting immunogenic polypeptides
US6143817A (en) 1998-10-07 2000-11-07 National Starch & Chemical Co. Use of derivatives of polyamino acids as emulsifiers stabilizers in aqueous free radical emulsion polymerization
AU1688099A (en) 1998-12-24 2000-07-31 Kyowa Hakko Kogyo Co. Ltd. Pharmaceutical preparation
EP1031354A3 (en) 1999-01-19 2003-02-05 Rohm And Haas Company Polymeric MRI Contrast agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040121954A1 (en) 1999-04-13 2004-06-24 Xu Wuhan Jingya Poly(dipeptide) as a drug carrier
US20010041189A1 (en) 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
US6326021B1 (en) 1999-06-18 2001-12-04 The Ohio State University Research Foundation Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US20030054977A1 (en) 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
CA2387611C (en) * 1999-10-12 2011-03-29 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6235264B1 (en) 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6685915B2 (en) 1999-12-01 2004-02-03 General Electric Company Extended-linear polymeric contrast agents, and synthesizing methods, for medical imaging
US20020077290A1 (en) 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US20020183243A1 (en) 2000-03-17 2002-12-05 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
CA2402643A1 (en) 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
WO2002000263A2 (en) 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
GB0018240D0 (en) 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
WO2002026241A1 (en) 2000-09-26 2002-04-04 Center For Advanced Science And Technology Incubation, Ltd. Polymeric micelle containing cisplatin enclosed therein and use thereof
US7097856B2 (en) 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US7070797B2 (en) 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
JP4462928B2 (ja) 2001-06-20 2010-05-12 日本化薬株式会社 不純物含有量の低減したブロック共重合体、高分子担体及び高分子医薬製剤並びにその製造方法
US20040043030A1 (en) 2001-07-31 2004-03-04 Immunomedics, Inc. Polymeric delivery systems
US20030049253A1 (en) 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
WO2003041642A2 (en) 2001-11-09 2003-05-22 Enzon, Inc. Polymeric thiol-linked prodrugs employing benzyl elimination systems
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US6939538B2 (en) 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
JP2004018494A (ja) * 2002-06-19 2004-01-22 Japan Science & Technology Corp ブロック共重合体−薬剤複合体の製造法
US20040047835A1 (en) 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
PT1580216E (pt) 2002-10-31 2014-07-31 Nippon Kayaku Kk Derivados de elevado peso molecular de camptotecinas
WO2004108667A2 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US6855695B2 (en) 2003-06-13 2005-02-15 Vion Pharmaceuticals, Inc. Water-soluble SHPs as novel alkylating agents
US20050187147A1 (en) 2003-09-22 2005-08-25 Newman Michael J. Compositions and methods for increasing drug efficiency
US20050118718A1 (en) 2003-09-22 2005-06-02 University Of Utah Research Foundation Stabilization and controlled delivery of ionic biopharmaceuticals
DE602004025612D1 (de) 2003-12-10 2010-04-01 Toudai Tlo Ltd Koordinationskomplex von diaminocyclohexanplatin(ii) mit einem blockcopolymer mit einem poly(carbonsäure)segment und diesen enthaltendes antitumormittel
WO2005063304A2 (en) 2003-12-24 2005-07-14 Board Of Regents, The University Of Texas_System Poly (l-glutamic acid) paramagnetic material complex and use as a biodegradable mri contrast agent
WO2005079861A2 (en) * 2004-02-13 2005-09-01 Safeway Investments Ltd. Polymeric water soluble prodrugs
EP1722762A2 (en) 2004-03-02 2006-11-22 Massachusetts Institute of Technology Nanocell drug delivery system
US7317070B1 (en) * 2004-03-12 2008-01-08 Sigma-Aldrich Co. Process for the preparation of polyamino acids
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050271585A1 (en) 2004-06-07 2005-12-08 General Electric Company Extended conjugated polymers
US20050276783A1 (en) 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006041613A2 (en) * 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
RU2472812C2 (ru) * 2005-12-05 2013-01-20 НИТТО ДЕНКО КОРПОРЭЙШН (Джэпэн/Джэпэн) Конъюгаты полиглутамат-аминокислота и способы
US20080051603A1 (en) 2006-06-15 2008-02-28 Cell Therapeutics, Inc. Process for the preparation of poly-alpha-glutamic acid and derivatives thereof
US20080181852A1 (en) 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
JP2010526917A (ja) 2007-05-09 2010-08-05 日東電工株式会社 複数種の薬物を有するポリグルタミン酸塩複合体及びポリグルタミン酸塩−アミノ酸複合体
DK2155254T3 (da) * 2007-05-09 2013-03-04 Nitto Denko Corp Med platinlægemidler konjugerede polymere
JP5341879B2 (ja) 2007-05-09 2013-11-13 日東電工株式会社 疎水性化合物及びポリアミノ酸複合体を含む組成物
EP2262537A1 (en) 2008-03-06 2010-12-22 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
US20100093935A1 (en) 2008-10-15 2010-04-15 Nitto Denko Corporation Method of preparing polyglutamate conjugates
WO2011075483A1 (en) 2009-12-16 2011-06-23 Nitto Denko Corporation Controlled synthesis of polyglutamic acid
AU2011224374A1 (en) 2010-03-11 2012-09-27 Nitto Denko Corporation Carbohydrate-polyamino acid-drug conjugates
WO2012027204A1 (en) 2010-08-26 2012-03-01 Nitto Denko Corporation End-capped polymers

Also Published As

Publication number Publication date
CN101678123A (zh) 2010-03-24
PT2155255E (pt) 2013-10-15
EP2155255A2 (en) 2010-02-24
JP5341879B2 (ja) 2013-11-13
WO2008141107A8 (en) 2009-06-18
CA2683590A1 (en) 2008-11-20
WO2008141107A2 (en) 2008-11-20
KR20100017540A (ko) 2010-02-16
US8329199B2 (en) 2012-12-11
CN101678123B (zh) 2014-07-16
EP2155255B1 (en) 2013-08-14
WO2008141107A3 (en) 2009-04-23
ES2430380T3 (es) 2013-11-20
US8197828B2 (en) 2012-06-12
DK2155255T3 (da) 2013-09-02
JP2010526829A (ja) 2010-08-05
US20080279777A1 (en) 2008-11-13
US20120230917A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
JP5237821B2 (ja) ポリグルタミン酸−アミノ酸結合体および方法
CN101631567B (zh) 多功能药物载体
TW200900083A (en) Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
JP2010526159A (ja) 多機能性ポリグルタミン酸塩薬物担体
CN101730549B (zh) 与铂类药物结合的聚合物
JP2011513412A (ja) ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
US8329199B2 (en) Compositions that include a hydrophobic compound and a polyamino acid conjugate
US20120052015A1 (en) End-capped polymers